scholarly journals Clinical Characteristics of Cerebral Venous Thrombosis in a Single Center in Korea

2014 ◽  
Vol 56 (4) ◽  
pp. 289 ◽  
Author(s):  
Dong Sun Park ◽  
Chang Taek Moon ◽  
Young Il Chun ◽  
Young-Cho Koh ◽  
Hahn Young Kim ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Clinical Characteristics ◽  
Single Center

Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience

2021 ◽  
Author(s):  
Zoltan Bajko ◽  
Smaranda Maier ◽  
Anca Motataianu ◽  
Rares Cristian Filep ◽  
Adina Stoian ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Single Center ◽  
Single Center Experience

Abstract W P318: Declining Mortality in Cerebral Venous Thrombosis: A Systematic Review

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Jonathan M Coutinho ◽  
Susanna M Zuurbier ◽  
Jan Stam
Keyword(s):  
Systematic Review ◽  
Venous Thrombosis ◽  
Low Income ◽  
Cerebral Venous Thrombosis ◽  
Inverse Correlation ◽  
Low Income Countries ◽  
Single Center ◽  
Clear Trend ◽  
Only Children ◽  
Number Of Patients

Introduction: Cerebral venous thrombosis (CVT) is nowadays considered a disease with a good outcome in most cases, but in the past these patients were believed to have a grave prognosis. This apparent decline in mortality has not been investigated systematically Methods: We performed a systematic review of the literature. Older studies were identified from books and by scanning reference lists. Studies with 40 CVT patients or more that minimally reported mortality at discharge were eligible. Care was taken to exclude duplicate publications based on the same patient cohort. Studies were ranked according to the year halfway the period of patient inclusion. If no time span was reported, we assumed a period of inclusion of 10 years prior to the year of publication. Results: Of 4.585 potentially eligible studies, 74 fulfilled the selection criteria and were included in the analysis. The majority of studies were retrospective (80%) and single-center (59%). In total, 23.031 patients were included in the analysis. The number of patients per study varied from 40 to 11.400 (median 79). Seven studies included only children. There was a significant inverse correlation between mortality and year of patient recruitment (Pearson’s correlation coefficient -0.70, p<0.001, figure). In a sensitivity analysis, exclusion of retrospective studies, pediatric studies, single-center studies, or studies from low income countries did not significantly alter the correlation. Conclusions: There is a clear trend in declining mortality among patients with CVT over time. Possible explanations include better diagnosis (with identification of less severe cases), improved treatment and a declining incidence of infection related CVT.

A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis

2020 ◽  
pp. 106002802095274
Author(s):  
Marissa Powell ◽  
Kathryn Tremolet de Villers ◽  
Kerry Schwarz ◽  
David Case ◽  
Toby Trujillo
Keyword(s):  
Venous Thrombosis ◽  
Anticoagulant Therapy ◽  
Cerebral Venous Thrombosis ◽  
Factor Xa ◽  
Factor Xa Inhibitors ◽  
Factor Xa Inhibitor ◽  
Single Center ◽  
Persistent Symptoms ◽  
Secondary Outcomes

Background: Clinical practice guidelines recommend that cerebral venous thrombosis (CVT) be managed with long-term anticoagulant therapy using warfarin or low-molecular-weight heparin (LMWH) for 3 to 12 months. However, oral factor Xa inhibitors may offer preferable alternative treatment options for these patients. Objective: The primary objective was to determine the effectiveness and safety of rivaroxaban or apixaban compared with warfarin or enoxaparin as long-term anticoagulation therapy for patients with a new diagnosis of CVT. Methods: This was a single-center retrospective review of patients with newly diagnosed CVT who received acute and maintenance anticoagulation treatment. Study groups compared patients who received warfarin, enoxaparin, or an oral factor Xa inhibitor as their maintenance anticoagulant. The primary outcome was recurrent thrombotic events while on anticoagulation. Secondary outcomes included modified Rankin Scale, improved cerebral venous sinus opacification, duration of anticoagulant therapy, bleeding events during anticoagulant therapy, and adverse effects. Results: A total of 119 patients were included in the analysis: warfarin (89), enoxaparin (11), and oral factor Xa inhibitor (19). The risk of recurrent thrombotic events were 11.2%, 0%, and 10.5% in the warfarin, enoxaparin, and oral factor Xa inhibitor treatment groups, respectively ( P = 0.7635). There were no significant between-group differences observed regarding any of the secondary outcomes. Conclusions: Although the sample size is limited, these findings indicate that oral factor Xa inhibitors are a reasonable treatment option for patients with CVT. There was a trend toward more persistent symptoms in patients on warfarin, suggesting a potential improvement in recovery among patients that received an oral factor Xa inhibitor.

scholarly journals Bacterial meningitis complicated by cerebral venous thrombosis

2020 ◽  
Vol 5 (4) ◽  
pp. 394-401
Author(s):  
Shahrzad S Deliran ◽  
Matthijs C Brouwer ◽  
Jonathan M Coutinho ◽  
Diederik van de Beek
Keyword(s):  
Bacterial Meningitis ◽  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Clinical Characteristics ◽  
Clinical Course ◽  
Rare Complication ◽  
Transverse Sinus ◽  
Causative Pathogen ◽  
Neurologic Deficits ◽  
Nose And Throat

Introduction Community-acquired bacterial meningitis may be complicated by cerebral venous thrombosis (CVT), but this has not systematically been studied. Methods We evaluated clinical characteristics and outcome of CVT in adults with community-acquired bacterial meningitis in a prospective nationwide cohort study of bacterial meningitis (2006–2018) in the Netherlands. Results CVT occurred in 26 of 2220 episodes with bacterial meningitis (1%). The diagnosis of CVT was made on the day of presentation in 15 patients (58%) and during hospital stay in 11 patients after a median of 6 days (IQR 2–7). Sinusitis or otitis was present in 16 of 24 patients (67%). Patients with CVT presented more often in a coma than those without CVT (53 vs. 18%; P = 0.001) and the clinical course was more often complicated by focal neurologic deficits (58 vs. 22%; P < 0.001). Twelve patients of 26 (46%) had parenchymal lesions on neuroimaging, of whom two (8%) were specific for CVT. The transverse sinus was most frequently thrombosed (18 of 26; 69%). Streptococcus pneumoniae was the most common causative pathogen, occurring in 17 of 26 patients (65%). Eleven patients (44%) received anticoagulant therapy with heparin and none of them developed intracerebral hemorrhage during admission. Unfavorable outcome, as defined as a score on the Glasgow Outcome Scale <5, occurred in 14 of 26 patients (54%) and 4 patients (15%) died. Discussion and conclusion CVT is a rare complication of bacterial meningitis and mainly occurs in patients with coma, ear, nose and throat infections, and focal neurologic deficits.

Sign in / Sign up

Export Citation Format

Share Document